Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gynecologic 1CNS 1

Conditions

Neuroblastoma 51Central Nervous System Neoplasms 43Medulloblastoma 22Brain Neoplasms 20Astrocytoma 15Oligodendroglioma 14Rhabdoid Tumor 7Choroid Plexus Neoplasms 7Neoplasms 6Glioma 6Optic Nerve Glioma 5Ganglioneuroblastoma 5Spinal Cord Neoplasms 4Sarcoma 4Neuroectodermal Tumors, Primitive 4Glioblastoma 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Recurrence 3Lymphoma 3Gliosarcoma 3Ependymoma 3Wilms Tumor 2Pinealoma 2Neurofibromatosis 1 2Familial ependymoma 2Untreated Childhood Medulloblastoma 1Retinoblastoma 1Pyloric Stenosis, Hypertrophic 1Ototoxicity 1

Interventions

silmitasertib 1sargramostim 1Vincristine 1Trabectedin 1Temozolomide 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Drug Therapy 1Cyproheptadine 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma × Vincristine × CNS × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡